AACHEN, Germany, July 8, 2026 /PRNewswire/ -- Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD)....
Hence then, the article about grunenthal receives fda orphan drug and rare pediatric disease designations for tegacorat for the treatment of duchenne muscular dystrophy was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy )
Also on site :
- In 2008, Celine Dion bought a lot on Florida’s Jupiter Island for $7 million; her water park mansion there sold 9 years later for $28 million
- Dwayne Johnson and Oprah Winfrey gave $10 million to launch the People’s Fund of Maui for wildfire survivors
- In 2017, Jack Daniel’s named Nathan “Nearest” Green its first master distiller for teaching the brand’s founder to distill whiskey over a century earlier